Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
CAD106 Alzheimer's Disease (Phase 2/3) Novartis Pharmaceuticals Corporation Amyloid-Related Immunotherapy (active) None
CNP520 BACE Inhibitor Alzheimer's Disease (Phase 2/3) Amgen, Inc., Novartis Pharmaceuticals Corporation Amyloid-Related Small Molecule
Epigallocatechin Gallate (EGCG) Sunphenon EGCg Alzheimer's Disease (Phase 2/3), Down's Syndrome (Phase 2), Multiple System Atrophy (Phase 3) Taiyo International Amyloid-Related, Inflammation, Other Dietary Supplement
Gamunex Intravenous Immunoglobulin,
Human Albumin Combined With Flebogamma
Alzheimer's Disease (Phase 2/3) Grifols Biologicals Inc. Amyloid-Related, Inflammation Immunotherapy (passive) Immunodeficiency, chronic inflammatory demyelinating neuropathy
JNJ-54861911 BACE inhibitor Alzheimer's Disease (Phase 2/3) Janssen, Shionogi Pharma Amyloid-Related Small Molecule
Thalidomide Thalomid® Alzheimer's Disease (Phase 2/3) Celgene Corporation Amyloid-Related, Inflammation Small Molecule